Navigation Links
Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
Date:4/14/2009

PHILADELPHIA Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

Pancreatic cancer is one of the deadliest cancers, and less than 4 percent of the 200,000 patients diagnosed annually live more than five years. The only available clinical treatment is gemcitabine, but this has yet to show a survival benefit.

Scientists are testing a variety of experimental therapies to bring pancreatic cancer under control. At Amgen, Pedro J. Beltran, Ph.D., a principal scientist in oncology research, is experimenting with AMG 479, a fully human anti-IGF-1 monoclonal antibody.

"We know that insulin-like growth factors play a role in cancer development, particularly in mediating cell survival. This is the first drug that specifically targets the receptor for these growth factors without cross-reacting with the closely related insulin receptor," said Beltran.

In the in vitro study, AMG 479 bound to IGF-1R and blocked both IGF-1 and IGF-2 binding factors 1 and 2. It also completely inhibited ligand-induced activation in some growth factors, which led to a decreased cellular viability. When Beltram and colleagues measured the effect of AMG 479 on pancreatic cancer cells in vivo, the inhibition rate was approximately 80 percent inhibition of tumor growth and receptor expression was observed.

"These data clearly show that AMG 479 is a clinical candidate for pancreatic cancer therapy, either alone or in combination with gemcitabine," he said.

Beltran said researchers are currently testing AMG 479 in nine separate phase II studies of various cancer types; he expects the effect will be seen beyond pancreatic cancer.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... York, NY (PRWEB) , ... June 19, 2017 , ... ... this year, it’s going to be a humdinger. A warm winter and wet spring ... summer wedding guests. “No one wants to be swatting away pesky mosquitoes when a ...
(Date:6/19/2017)... , ... June 19, 2017 , ... ... designed to foster the international exchange of actionable insights to improve health ... discussing its mission to make clinical trial management faster, easier, and less painful. ...
(Date:6/19/2017)... ... June 19, 2017 , ... Intalere, the healthcare industry leader ... Show at its Elevate 2017 meeting in Orlando, Fla. The event featured diversity ... products and services to Intalere members. , “Intalere is dedicated to providing our ...
(Date:6/19/2017)... ... June 19, 2017 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/19/2017)... ... June 19, 2017 , ... Aeroflow Breastpumps announced their partnership ... insurance plans to families and individuals who qualify for government-sponsored programs such as ... for Molina members effective July 2017. , “We are delighted to partner ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... Israel , May 30, 2017 Therapix ... pharmaceutical Company specializing in the development of cannabinoid-based ... present a company overview at three upcoming scientific ... 7th Annual LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... , May 25, 2017  In response to the ... , Direct Relief is working with Pfizer to make ... at no cost to community health centers, free and ... nationwide. "Pfizer has a long-standing commitment ... and ensuring patient safety through educational activities," said ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, the ... announces the launch of a new website ... results of a clinical study that showed surprising ... with Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, ... that there are no other treatments that clear ...
Breaking Medicine Technology: